Format

Send to

Choose Destination
See comment in PubMed Commons below
Antiviral Res. 2014 Apr;104:73-83. doi: 10.1016/j.antiviral.2014.01.018. Epub 2014 Jan 31.

Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.

Author information

  • 1Samsung Advanced Institute for Health Sciences and Technology (SAIHST) and Samsung Biomedical Research Institute (SBRI), Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea.
  • 2Infectious Diseases Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, United States; Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, United States.
  • 3Samsung Advanced Institute for Health Sciences and Technology (SAIHST) and Samsung Biomedical Research Institute (SBRI), Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea; Infectious Diseases Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, United States; Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, United States. Electronic address: mkang@skku.edu.

Abstract

The replication and persistence of extra chromosomal Epstein-Barr virus (EBV) episome in latently infected cells are primarily dependent on the binding of EBV-encoded nuclear antigen 1 (EBNA1) to the cognate EBV oriP element. In continuation of the previous study, herein we characterized EBNA1 small molecule inhibitors (H20, H31) and their underlying inhibitory mechanisms. In silico docking analyses predicted that H20 fits into a pocket in the EBNA1 DNA binding domain (DBD). However, H20 did not significantly affect EBNA1 binding to its cognate sequence. A limited structure-relationship study of H20 identified a hydrophobic compound H31, as an EBNA1 inhibitor. An in vitro EBNA1 EMSA and in vivo EGFP-EBNA1 confocal microscopy analysis showed that H31 inhibited EBNA1-dependent oriP sequence-specific DNA binding activity, but not sequence-nonspecific chromosomal association. Consistent with this, H31 repressed the EBNA1-dependent transcription, replication, and persistence of an EBV oriP plasmid. Furthermore, H31 induced progressive loss of EBV episome. In addition, H31 selectively retarded the growth of EBV-infected LCL or Burkitt's lymphoma cells. These data indicate that H31 inhibition of EBNA1-dependent DNA binding decreases transcription from and persistence of EBV episome in EBV-infected cells. These new compounds might be useful probes for dissecting EBNA1 functions in vitro and in vivo.

Copyright © 2014 Elsevier B.V. All rights reserved.

KEYWORDS:

EBNA1; EBV; Inhibitor; Persistence; Small molecule; oriP

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk